BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 2, 2013
View Archived Issues
Vectura and UCB collaborate on severe inflammatory diseases
Read More
ODM-201 shows efficacy in patients with mCRPC
Read More
Discovery and characterization of a novel selective class of anticancer agents
Read More
New French biotechnology company formed to develop MAb for ovarian cancer
Read More
New FimH inhibitors presented by Vertex Pharmaceuticals
Read More
Researchers present promising data for the VEGFR inhibitor cediranib
Read More
MEDI-4736 treatment results in significant tumor suppression
Read More
FDA clears Beckman Coulter's AccuTnI+3 troponin I assay for UniCel DxI immunoassay systems
Read More
VitamFero expands its assets with new vaccine against ocular toxoplasmosis
Read More
NICE recommends Genomic Health's Oncotype DX test
Read More
MabVax receives SBIR grant for novel pancreatic cancer diagnostic
Read More
Moleculin reports encouraging data from phase IIa trial of novel topical psoriasis treatment
Read More
Phase II data available for palbociclib in liposarcoma; phase III study planned
Read More
Researchers at Boehringer Ingelheim patent novel MCH-R1 antagonists
Read More
Karus Therapeutics synthesizes new PI3Kbeta/delta inhibitors
Read More
Amgen patents novel tankyrase inhibitors and Wnt activators
Read More
Researchers at the University of Maryland divulge new vaccine formulations
Read More
GSK to sell thrombosis brands and related manufacturing site to Aspen
Read More
Circassia's grass allergy treatment achieves significant symptom reduction in phase II study
Read More
FDA grants accelerated approval of new indication for Perjeta
Read More
Bone Therapeutics receives clearance to conduct phase I/IIa ALLOB trial
Read More
Sun Pharmaceutical and Intrexon to develop new class of drugs for ocular diseases
Read More
FDA accepts NDA for tavaborole
Read More
Study of LX-4211 in type 2 diabetes patients with renal impairment meets endpoint
Read More
Phase I/II trial of Mologen's renal cancer vaccine meets primary endpoints
Read More
Antihyperglycemia compound has novel molecular mechanism of action
Read More
Novartis initiates pivotal study of HuCAL-derived antibody bimagrumab
Read More